Eidos Therapeutics, Inc.
(NASDAQ : EIDX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
0.76%195.471.3%$555.99m
GILDGilead Sciences, Inc.
0.24%66.520.9%$368.70m
ALXNAlexion Pharmaceuticals, Inc.
-0.79%107.402.0%$321.44m
ILMNIllumina, Inc.
1.14%300.913.5%$301.00m
BIIBBiogen Inc.
1.86%236.631.3%$288.49m
CELGCelgene Corporation
-0.23%98.401.3%$282.90m
AAgilent Technologies, Inc.
0.43%77.901.6%$193.04m
SRPTSarepta Therapeutics, Inc.
-2.25%86.0014.7%$180.31m
VRTXVertex Pharmaceuticals Incorporated
1.44%174.941.9%$173.66m
REGNRegeneron Pharmaceuticals, Inc.
-0.90%281.622.6%$171.53m
EXASExact Sciences Corporation
-1.82%106.7124.1%$132.03m
ACADACADIA Pharmaceuticals Inc.
3.35%40.4513.9%$98.63m
INCYIncyte Corporation
0.47%76.432.5%$83.43m
BMRNBioMarin Pharmaceutical Inc.
-0.21%72.654.3%$76.16m
IONSIonis Pharmaceuticals, Inc.
-1.02%66.208.2%$63.42m

Company Profile

Eidos Therapeutics, Inc. focuses on addressing the large and growing unmet need in diseases caused by transthyretin (TTR) amyloidosis (ATTR). Its product include the AG10, an orally-administered small molecule designed to potently stabilize TTR, suggesting a treatment with the potential to halt the progression of ATTR. The company was founded by Graef Isabella and Alhamadsheh Mamoun on August 6, 2013 and is headquartered in San Francisco, CA.